Terminated × Interventional × Triple Negative Breast Neoplasms × Clear all EPIK-B3
Phase 3 Terminated
137 enrolled 21 charts
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Phase 1/2 Terminated
8 enrolled 13 charts
AMTEC IIT: Phase 2 Multiarm Study in TNBC
Phase 2 Terminated
24 enrolled 16 charts
PRO1107 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
33 enrolled
INTEGRAL
Phase 2 Terminated
8 enrolled 10 charts
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
neoMono
Phase 2 Terminated
442 enrolled 42 charts
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Phase 1 Terminated
78 enrolled
Olinvacimab With Pembrolizumab in Patients With mTNBC
Phase 2 Terminated
19 enrolled
Néo-APBI-01
Phase 1/2 Terminated
362 enrolled
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Phase 2 Terminated
24 enrolled
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Phase 2 Terminated
77 enrolled 18 charts
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Phase 1 Terminated
36 enrolled 7 charts
BIS-Program
Phase 2 Terminated
33 enrolled
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 1/2 Terminated
31 enrolled
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Phase 1 Terminated
154 enrolled
A Study of PF-06873600 in People With Cancer
Phase 1/2 Terminated
155 enrolled 44 charts
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Phase 2 Terminated
26 enrolled
MK-2140-002
Phase 2 Terminated
102 enrolled 36 charts
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
82 enrolled
ELEVATE TNBC
Phase 2 Terminated
92 enrolled 27 charts
TNBC
Phase 2 Terminated
115 enrolled 31 charts
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
Phase 2 Terminated
6 enrolled
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
23 enrolled
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
Phase 1/2 Terminated
10 enrolled 15 charts
MGC018 With or Without MGA012 in Advanced Solid Tumors
Phase 1/2 Terminated
143 enrolled 33 charts
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
11 enrolled
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
Phase 2 Terminated
25 enrolled
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase 1/2 Terminated
19 enrolled
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 23 charts
A Study to Investigate LYL797 in Adults With Solid Tumors
Phase 1 Terminated
57 enrolled
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Phase 1/2 Terminated
5 enrolled
AVID100 in Advanced Epithelial Carcinomas
Phase 1/2 Terminated
49 enrolled 19 charts
neoBREASTIM
Phase 1/2 Terminated
2 enrolled
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
PERSEVERE
Phase 2 Terminated
52 enrolled 16 charts
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 33 charts
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Phase 1 Terminated
64 enrolled
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
Phase 1/2 Terminated
15 enrolled
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Phase 1/2 Terminated
222 enrolled 49 charts
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
Phase 2 Terminated
9 enrolled
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
Phase 2 Terminated
30 enrolled 16 charts
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Phase 1 Terminated
127 enrolled
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Phase 2 Terminated
315 enrolled 73 charts
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
Phase 2 Terminated
6 enrolled 8 charts
Sitravatinib in Metastatic Breast Cancer
Phase 2 Terminated
3 enrolled 13 charts